Reverb Therapeutics
Reverb Therapeutics is a Vancouver-based, preclinical stage biotechnology company with an exciting new technology. Reverb’s AmplifyR™ platform uses bi-specific antibodies to redirect the body’s own cytokines and concentrates them to assist natural healing by the immune system. This approach ensures that the immune system acts locally where it is needed most, and not throughout the body. Because it uses the body’s own cytokines, AmplifyR™ therapies are thought to be much better tolerated than traditional therapeutics. AmplifyR™ drugs are also easy to manufacture. The lead program is directed against a set of cancers that respond poorly to current therapies and is expected to enter clinical trials within two years. Reverb is also initiating programs that will address the overactive immune system in auto-immune diseases. The team is led by David De Graaf (President & CEO) and Surjit Dixit (CSO). Learn more.
